# AGO1

## Overview
AGO1 is a gene that encodes the protein argonaute RISC component 1, a pivotal element in the RNA-induced silencing complex (RISC) involved in gene regulation through RNA interference (RNAi) mechanisms. As a member of the Argonaute protein family, AGO1 plays a crucial role in post-transcriptional gene silencing by binding to microRNAs (miRNAs) and small interfering RNAs (siRNAs), facilitating the repression or degradation of target mRNAs. The protein is characterized by its distinct domains, including the PAZ, MID, and PIWI domains, which are essential for its interaction with small RNAs and target mRNAs. Although AGO1 lacks endonuclease activity, it is integral to transcriptional gene silencing and chromatin remodeling, influencing gene expression and cellular homeostasis (Meister2013Argonaute; Hutvagner2008Argonaute). Mutations and dysregulation of AGO1 have been implicated in various diseases, including neurodevelopmental disorders and cancer, highlighting its significance in both normal physiology and disease states (Fain2024DNA; Schalk2021De).

## Structure
AGO1, a human Argonaute protein, is integral to the RNA-induced silencing complex (RISC) and is involved in gene regulation through RNA silencing mechanisms. The protein is composed of several domains: N, PAZ, MID, and PIWI, which are organized in a bilobed architecture. The N-terminal lobe contains the N and PAZ domains, while the C-terminal lobe includes the MID and PIWI domains, creating a central cleft that accommodates guide and target nucleic acids (Nakanishi2022Anatomy; Schirle2012Structure).

The PAZ domain binds the 3' end of the guide RNA, while the MID domain anchors the 5' phosphate, facilitating the interaction with small regulatory RNAs (Schirle2012Structure). The PIWI domain, which has an RNase H-like fold, is responsible for the endonuclease activity, although AGO1 itself lacks slicer activity (Hutvagner2008Argonaute; Kobayashi2016RISC).

Mutations in AGO1, such as the Gly199 to Ser mutation, can alter the protein's structure by affecting the twisted antiparallel β-strands that support the PAZ domain, potentially impacting its function (Nakanishi2022Anatomy). Post-translational modifications, including phosphorylation, can regulate AGO1's activity and interactions with mRNAs (Nakanishi2022Anatomy).

## Function
AGO1 (argonaute RISC component 1) is a key player in RNA interference (RNAi) and gene silencing processes in human cells. It is a core component of the RNA-induced silencing complex (RISC), where it binds to microRNAs (miRNAs) and small interfering RNAs (siRNAs) to regulate gene expression post-transcriptionally. AGO1 facilitates the cleavage or translational repression of target mRNAs, impacting cellular functions and maintaining homeostasis (Meister2013Argonaute; Kobayashi2016RISC).

In healthy human cells, AGO1 is involved in transcriptional gene silencing (TGS) by directing siRNA-mediated silencing at specific gene promoters. It recruits histone methyltransferase activity to promote the dimethylation of histone H3 at lysine 9 (H3K9me2), a modification associated with gene silencing. This process is crucial for the formation of heterochromatin, a transcriptionally inactive form of DNA (Kim2006Argonaute1).

AGO1 also interacts with RNA polymerase II and is associated with actively transcribed gene promoters, suggesting a role in transcription regulation. This interaction is stable and DNA-dependent, indicating that AGO1 may influence gene expression through miRNA-dependent mechanisms (Huang2013Ago1). AGO1's functions are essential for regulating developmental processes and maintaining cellular homeostasis.

## Clinical Significance
Mutations and alterations in the AGO1 gene are associated with several diseases and conditions. De novo coding variants in AGO1 have been linked to a neurodevelopmental disorder characterized by intellectual disability, speech and motor delays, autistic behavior, and other behavioral manifestations. These variants often lead to amino acid changes or deletions, affecting the protein's function in mRNA processing and gene silencing pathways (Schalk2021De). Clinical features in affected individuals include borderline to severe intellectual disability, severe language delay, motor developmental delay, seizures, and various behavioral issues such as autistic traits and anxiety (Schalk2021De).

In cancer, AGO1 is involved in epigenetic alterations, particularly through DNA methylation changes. Hypomethylation of AGO1 can lead to the activation of cancer-germline genes, contributing to tumorigenesis. The AGO1-V2 isoform, a truncated version of AGO1, is expressed in certain tumors and is associated with altered miRNA regulation, potentially influencing cancer progression (Fain2024DNA).

In metabolic disorders, suppression of endothelial AGO1 has been shown to improve insulin sensitivity and promote adipose tissue browning, suggesting a role in obesity and insulin resistance (Tang2020Suppression). These findings highlight the clinical significance of AGO1 in various diseases, emphasizing its potential as a therapeutic target.

## Interactions
AGO1, a member of the Argonaute protein family, is involved in various interactions with proteins and nucleic acids that are crucial for its role in gene regulation. AGO1 interacts directly with RNA Polymerase II (RNAP II) in human cancer cells, a relationship that is essential for its function in transcriptional regulation. This interaction is specific to AGO1, as AGO2 does not show the same association with RNAP II (Huang2013Ago1). AGO1 also associates with chromatin and transcriptional enhancers, where it is involved in the regulation of enhancer RNA (eRNA) transcription, suggesting a role in maintaining chromatin architecture and gene expression (Shuaib2019Nuclear).

AGO1 is enriched at transcriptionally active enhancers and interacts with enhancer RNAs, which stabilize its association with chromatin. This interaction is crucial for AGO1's role in chromatin organization and gene regulation (Shuaib2019Nuclear). AGO1 also forms complexes with other proteins, such as TRBP2, which is necessary for transcriptional gene silencing (TGS) by recruiting histone methyltransferase activity (Kim2006Argonaute1). These interactions highlight AGO1's multifaceted role in gene expression regulation through its association with both proteins and nucleic acids.


## References


[1. (Fain2024DNA) Jean S. Fain, Camille Wangermez, Axelle Loriot, Claudia Denoue, and Charles De Smet. Dna hypomethylation underlies epigenetic swapping between ago1 and ago1-v2 isoforms in tumors. Epigenomes, 8(3):24, June 2024. URL: http://dx.doi.org/10.3390/epigenomes8030024, doi:10.3390/epigenomes8030024. This article has 0 citations.](https://doi.org/10.3390/epigenomes8030024)

[2. (Meister2013Argonaute) Gunter Meister. Argonaute proteins: functional insights and emerging roles. Nature Reviews Genetics, 14(7):447–459, June 2013. URL: http://dx.doi.org/10.1038/nrg3462, doi:10.1038/nrg3462. This article has 833 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrg3462)

[3. (Kim2006Argonaute1) Daniel H Kim, Louisa M Villeneuve, Kevin V Morris, and John J Rossi. Argonaute-1 directs sirna-mediated transcriptional gene silencing in human cells. Nature Structural &amp; Molecular Biology, 13(9):793–797, August 2006. URL: http://dx.doi.org/10.1038/nsmb1142, doi:10.1038/nsmb1142. This article has 325 citations.](https://doi.org/10.1038/nsmb1142)

[4. (Kobayashi2016RISC) Hotaka Kobayashi and Yukihide Tomari. Risc assembly: coordination between small rnas and argonaute proteins. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1859(1):71–81, January 2016. URL: http://dx.doi.org/10.1016/j.bbagrm.2015.08.007, doi:10.1016/j.bbagrm.2015.08.007. This article has 232 citations.](https://doi.org/10.1016/j.bbagrm.2015.08.007)

[5. (Huang2013Ago1) Vera Huang, Jiashun Zheng, Zhongxia Qi, Ji Wang, Robert F. Place, Jingwei Yu, Hao Li, and Long-Cheng Li. Ago1 interacts with rna polymerase ii and binds to the promoters of actively transcribed genes in human cancer cells. PLoS Genetics, 9(9):e1003821, September 2013. URL: http://dx.doi.org/10.1371/journal.pgen.1003821, doi:10.1371/journal.pgen.1003821. This article has 103 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1003821)

[6. (Tang2020Suppression) Xiaofang Tang, Yifei Miao, Yingjun Luo, Kiran Sriram, Zhijie Qi, Feng-Mao Lin, Yusu Gu, Chih-Hung Lai, Chien-Yi Hsu, Kirk L. Peterson, Kendall Van Keuren-Jensen, Patrick T. Fueger, Gene W. Yeo, Rama Natarajan, Sheng Zhong, and Zhen Bouman Chen. Suppression of endothelial ago1 promotes adipose tissue browning and improves metabolic dysfunction. Circulation, 142(4):365–379, July 2020. URL: http://dx.doi.org/10.1161/CIRCULATIONAHA.119.041231, doi:10.1161/circulationaha.119.041231. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/CIRCULATIONAHA.119.041231)

[7. (Schalk2021De) Audrey Schalk, Margot A Cousin, Nikita R Dsouza, Thomas D Challman, Karen E Wain, Zoe Powis, Kelly Minks, Aurélien Trimouille, Eulalie Lasseaux, Didier Lacombe, Chloé Angelini, Vincent Michaud, Julien Van-Gils, Nino Spataro, Anna Ruiz, Elizabeth Gabau, Elliot Stolerman, Camerun Washington, Ray Louie, Brendan C Lanpher, Jennifer L Kemppainen, Micheil Innes, Frank Kooy, Marije Meuwissen, Alice Goldenberg, Francois Lecoquierre, Gabriella Vera, Karin E M Diderich, Beth Sheidley, Christelle Moufawad El Achkar, Meredith Park, Fadi F Hamdan, Jacques L Michaud, Ann J Lewis, Christiane Zweier, André Reis, Matias Wagner, Heike Weigand, Hubert Journel, Boris Keren, Sandrine Passemard, Cyril Mignot, Koen van Gassen, Eva H Brilstra, Gina Itzikowitz, Emily O’Heir, Jake Allen, Kirsten A Donald, Bruce Richard Korf, Tammi Skelton, Michelle Thompson, Nathaniel H Robin, Natasha L Rudy, William B Dobyns, Kimberly Foss, Yuri Alexander Zarate, Katherine A Bosanko, Yves Alembik, Benjamin Durand, Frederic Tran Mau-them, Emmanuelle Ranza, Xavier Blanc, Stylianos E Antonarakis, Kirsty McWalter, Erin Torti, Francisca Millan, Amy Dameron, Mari Tokita, Michael T Zimmermann, Eric W Klee, Amelie Piton, and Benedicte Gerard. De novo coding variants in the ago1 gene cause a neurodevelopmental disorder with intellectual disability. Journal of Medical Genetics, 59(10):965–975, December 2021. URL: http://dx.doi.org/10.1136/jmedgenet-2021-107751, doi:10.1136/jmedgenet-2021-107751. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2021-107751)

[8. (Nakanishi2022Anatomy) Kotaro Nakanishi. Anatomy of four human argonaute proteins. Nucleic Acids Research, 50(12):6618–6638, June 2022. URL: http://dx.doi.org/10.1093/nar/gkac519, doi:10.1093/nar/gkac519. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkac519)

[9. (Hutvagner2008Argonaute) Gyorgy Hutvagner and Martin J. Simard. Argonaute proteins: key players in rna silencing. Nature Reviews Molecular Cell Biology, 9(1):22–32, January 2008. URL: http://dx.doi.org/10.1038/nrm2321, doi:10.1038/nrm2321. This article has 1028 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrm2321)

[10. (Schirle2012Structure) Nicole T. Schirle and Ian J. MacRae. Structure and Mechanism of Argonaute Proteins, pages 83–100. Elsevier, 2012. URL: http://dx.doi.org/10.1016/B978-0-12-404741-9.00004-0, doi:10.1016/b978-0-12-404741-9.00004-0. This article has 13 citations.](https://doi.org/10.1016/B978-0-12-404741-9.00004-0)

[11. (Shuaib2019Nuclear) Muhammad Shuaib, Krishna Mohan Parsi, Manjula Thimma, Sabir Abdu Adroub, Hideya Kawaji, Loqmane Seridi, Yanal Ghosheh, Alexandre Fort, Bodor Fallatah, Timothy Ravasi, Piero Carninci, and Valerio Orlando. Nuclear ago1 regulates gene expression by affecting chromatin architecture in human cells. Cell Systems, 9(5):446-458.e6, November 2019. URL: http://dx.doi.org/10.1016/j.cels.2019.09.005, doi:10.1016/j.cels.2019.09.005. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.cels.2019.09.005)